Royal Bank of Canada Has $1.08 Billion Holdings in Stryker Corporation $SYK

Royal Bank of Canada lessened its holdings in Stryker Corporation (NYSE:SYK) by 8.0% during the fourth quarter, HoldingsChannel reports. The fund owned 3,073,369 shares of the medical technology company’s stock after selling 268,486 shares during the quarter. Royal Bank of Canada’s holdings in Stryker were worth $1,080,197,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the 4th quarter worth about $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker in the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter worth about $27,000. DJE Kapital AG acquired a new stake in shares of Stryker in the 4th quarter worth about $28,000. Finally, CGC Financial Services LLC acquired a new stake in shares of Stryker in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.9%

NYSE:SYK opened at $310.71 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a market cap of $119.11 billion, a price-to-earnings ratio of 35.96, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm has a 50-day moving average price of $315.51 and a two-hundred day moving average price of $342.88.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last quarter. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group lowered their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. William Blair restated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Finally, Barclays decreased their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.